When less is more: Maintenance therapy in colorectal cancer

The Lancet

Volumn 385, Issue 9980, 2015, Pages 1808-1810

  Hubbard, Joleen M ^a   Grothey, Axel ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; HUMAN; MAINTENANCE THERAPY; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; FEMALE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84929516680     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62350-3     Document Type: Note

References (11)

1. A Grothey, D Sargent, RM Goldberg, HJ Schmoll Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209 1214
2. RM Goldberg, DJ Sargent, RF Morton et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
3. LB Saltz, S Clarke, E Diaz-Rubio et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
4. J Bennouna, J Sastre, D Arnold et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 2013 29 37
5. E Van Cutsem, J Tabernero, R Lakomy et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
6. LHJ Simkens, H van Tinteren, A May et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group Lancet 2015 published online April 8. http://dx.doi.org/10.1016/S0140-6736(14)62004-3
7. C Allegra, C Blanke, M Buyse et al. End points in advanced colon cancer clinical trials: a review and proposal J Clin Oncol 25 2007 3572 3575
8. S Hegewisch-Becker, U Graeven, C Lerchenmüller et al. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (BEV), BEV alone or no treatment, following a 24-week first-line induction with FP, oxaliplatin (OX) and BEV for patients with metastatic colorectal cancer: mature data and subgroup analysis of the AIO KRK 0207 phase III study Ann Oncol 25 suppl 4 2014 iv167
9. Q Shi, A de Gramont, A Grothey et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database J Clin Oncol 33 2015 22 28
10. R Kaplan, T Maughan, A Crook et al. Evaluating many treatments and biomarkers in oncology: a new design J Clin Oncol 31 2013 4562 4568
11. H Schmoll, D Arnold, A De Gramont et al. MODUL - a multicentre randomised clinical trial of biomarker-driven therapy for the 1st-line maintenance treatment of metastatic colorectal cancer (mCRC): a signal-seeking approach Ann Oncol 25 suppl 4 2014 iv209